WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoParasitic infections
Abrir esta carpeta y ver su contenidoInsect and arachnid bites and stings
Abrir esta carpeta y ver su contenidoSuperficial fungal infections
Abrir esta carpeta y ver su contenidoSubcutaneous fungal infections
Abrir esta carpeta y ver su contenidoBacterial infections
Abrir esta carpeta y ver su contenidoViral infections
Abrir esta carpeta y ver su contenidoEczematous diseases
Abrir esta carpeta y ver su contenidoScaling diseases
Abrir esta carpeta y ver su contenidoPapulosquamous diseases
Ver el documentoCutaneous reactions to drugs
Abrir esta carpeta y ver su contenidoPigmentary disorders
Abrir esta carpeta y ver su contenidoPremalignant lesions and malignant tumours
Abrir esta carpeta y ver su contenidoPhotodermatoses
Abrir esta carpeta y ver su contenidoBullous dermatoses
Ver el documentoAlopecia areata
Ver el documentoUrticaria
Abrir esta carpeta y ver su contenidoConditions common in children
Ver el documentoAcne vulgaris
Ver el documentoPruritus
Ver el documentoTropical ulcers
Abrir esta carpeta y ver su contenidoAntimicrobial drugs
Abrir esta carpeta y ver su contenidoAntifugal drugs
Abrir esta carpeta y ver su contenidoAntiseptic agents
Abrir esta carpeta y ver su contenidoKeratoplastic and keratolytic agents
Abrir esta carpeta y ver su contenidoScabicides and pediculicides
Cerrar esta carpetaAnti-inflammatory and antipruritic drugs1
Ver el documentoBetamethasone
Ver el documentoCalamine lotion
Ver el documentoHydrocortisone
Ver el documentoPrednisolone
Abrir esta carpeta y ver su contenidoAntiallergics and drugs used in anaphylaxis
Abrir esta carpeta y ver su contenidoUltraviolet radiation-blocking agents (sunscreens)
Abrir esta carpeta y ver su contenidoMiscellaneous drugs
Abrir esta carpeta y ver su contenidoAnnex
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack cover
 

Betamethasone

Ointment or cream, 0.1% (as valerate)

General information

Betamethasone is a topical corticosteroid preparation of high potency. Its therapeutic effects result from vasoconstriction, reduction of membrane permeability, and suppression of mitotic activity and the immune response.

Clinical information

Uses

Short-term treatment of non-infectious dermatoses (including contact, atopic and seborrhoeic dermatitis, psoriasis and actinic prurigo).

Dosage and administration

Adults and children over 2 years: a thin layer of ointment should be applied to the affected area twice or three times daily. The frequency of application is gradually reduced as improvement occurs.

Contraindications

• Known hypersensitivity to corticosteroids.
• Infections of the skin.
• Age under 2 years.

Precautions

Prolonged therapy or treatment of large areas of skin should be avoided as adrenal suppression can occur.

Betamethasone should not be used on the face for more than 7 consecutive days.

If secondary infection occurs during treatment, betamethasone should be withdrawn and an appropriate antimicrobial given.

Use in pregnancy

Betamethasone should not be used in large amounts or for more than 2 weeks during pregnancy.

Adverse effects

Existing infections may be exacerbated.

Prolonged use can induce atrophy of the skin, particularly on the face and in skin-folds. This is characterized by thinning of the dermis, depigmentation, dilatation of superficial blood vessels and formation of striae.

Infants and young children are particularly susceptible to the local and systemic effects of topical corticosteroids. Prolonged use can result in hypercorticalism and suppression of the hypothalamic-pituitary-adrenal axis.

Storage

Cream and ointment should be stored in well-closed containers.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019